Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion Bio Wins $280K NIH Grant to Develop NIPT Assay

NEW YORK – Fluxion Biosciences said today that the National Institutes of Health awarded the firm a $284,132 Phase I research grant in September to develop its Spotlight non-invasive prenatal test. 

As part of the project, the Alameda, California-based firm will validate a model system for test development, integrate key test components, and conduct clinical testing to compare Spotlight NIPT performance to competitive NIPT screening assays. 

Fluxion said that it will base the new test on an isolation technology that selectively removes fetal cells from the mother's blood sample. The firm's researchers will then separate the cells and test them for chromosomal abnormalities and other genetic variants using the company's single-cell next-generation sequencing method. 

"We are honored to receive this NIH grant and excited to develop the capabilities of our cell-based NIPT assay," Fluxion CEO Jeff Jensen said in a statement. "Spotlight NIPT brings together several technologies pioneered here at Fluxion, and we look forward to advancing this important test to routine clinical use." 

Fluxion partnered with the Cleveland Clinic in March to further validate its liquid biopsy-based mutation variant caller technology for sequencing services. 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.